Clinical study on heart failure to use cholesterol-lowering statinNovember 14, 2005An advanced study launched at Yale School of Medicine is evaluating the role of statin therapy in patients with heart failure, one of the leading causes of hospitalization in people over age 65. While statins-drugs that inhibit cholesterol production in the liver-are used primarily to lower cholesterol levels, there is evidence that these drugs may also have beneficial effects on blood vessel function independent of cholesterol levels. Heart failure patients are known to have vascular dysfunction, but are impaired and not routinely considered for statin therapy. The Yale trial, "Short Term Effects of Statin on Vascular Function in Heart Failure," will assess vascular function before and after a short course of statin therapy in heart failure patients with normal cholesterol levels. The randomized trial will include 30 patients with mild to moderate chronic heart failure. Long-term statin therapy has led to improved vascular function in heart disease patients with high cholesterol, but there are no data available regarding the short-term effects of statin therapy in heart failure patients with normal cholesterol levels. This study will screen patients for high cholesterol and evaluate the potential impact of statins on the care of heart failure patients. Researchers, led by Stuart D. Katz, M.D., associate professor of internal medicine/cardiovascular medicine at Yale School of Medicine, will use a method called the Cholestech LDX System to check cholesterol/LDL levels in blood at the beginning and the end of the study. The method enhances physicians' ability to quickly identify patients with high risk of heart disease and offer treatment and/or counseling in the same office visit. According to the American Heart Association, cardiovascular disease has been the leading cause of death in the United States for over 100 years. While some risk factors, including smoking, have declined in recent years, high cholesterol remains prevalent. "Generating comprehensive, lab-accurate results in minutes will enable physicians to focus on prescribing the right treatment sooner and ensuring that patients are on the correct therapeutic mix, rather than chasing down lab results," said Katz. "We are optimistic that this pilot study will yield promising results." Yale University |
|||||||||||||||||||||
| Related Statin Current Events and Statin News Articles Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Statins show dramatic drug and cell dependent effects in the brain Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. Adding ezetimibe to atorvastatin improves lipid control Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone. Elevated arginase levels contribute to vascular eye disease such as diabetic retinopathy Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy. New heart disease risk score outperforms existing test An independent external validation of QRISK - a new score for predicting a person's risk of heart disease - has shown that it performs better than the existing test and should be recommended for use in the United Kingdom by the National Institute for Health and Clinical Excellence (NICE). New heart disease risk score should be recommended in the UK, say experts A new score for predicting a person's risk of heart disease performs better than the existing test and should be recommended for use in the United Kingdom by the National Institute for Health and Clinical Excellence (NICE). New tool finds best heart disease and stroke treatments for patients with diabetes Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke. More patients across the world lowering 'bad' cholesterol The percentage of patients lowering their elevated "bad" cholesterol to within target levels nearly doubled in the last decade, according to a multi-national survey reported in Circulation: Journal of the American Heart Association. Statins can protect against Alzheimer's disease, according to new study High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer's disease. More Statin Current Events and Statin News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||